Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 September 2022 | Story Anthony Mthembu | Photo Supplied
Letsatsi Lekhooa
Letsatsi Lekhooa, a UFS student who was selected to be part of the COP27 Simulation Model.

Nearly 150 students from across the world will gather in Egypt for the COP27 Simulation Model from 9 September to mid- October 2022. Among them will be Letsatsi Lekhooa, a Master of Science student specialising in Climate Change from the University of the Free State (UFS). 

Lekhooa was one of 150 students from a pool of more than 1 800 applicants across the world who were selected to be part of this prestigious initiative. “This opportunity is appealing, because as young people we need to work hard to not only ensure that we break through walls, but to also represent our university well everywhere we go,” Lekhooa indicated.

The COP27 Simulation Model

The COP27 Simulation Model, which is organised by the British University in Egypt along with the United Nations Development Programme (UNDP), is a worldwide climate conference led by and targeted at the youth. The conference is important for several reasons, such as encouraging conversations around climate action among the youth. As it stands, the initiative is split into two categories, which include the hybrid capacity-building programme that started in September, and the COP27 Mock Conference set to begin in October. Lekhooa is currently engaged in the online capacity-building programme, which he describes as a learning curve. “Every day I learn something new, and I enjoy it because the process is assisting me in learning more about this climate change issue,” Lekhooa expressed. 

The benefits of attending the COP27 Mock Conference

Although the first leg of the COP27 Simulation Model is online, Lekhooa will get the opportunity to travel to Egypt and physically be part of the COP27 Mock Conference on the campus of the British University in Egypt. As such, he hopes to take away as much as possible from the experience. “I hope to learn about the ways in which I can better communicate this climate change issue, not only in my home country of Lesotho, but generally in Southern Africa,” said Lekhooa. Furthermore, through his interactions with international scholars, he hopes to create and encourage a collaborative spirit to battle climate change. 

The experience does not only serve as a learning curve for Lekhooa, but it is also one of the key steps that will allow him to reach a life goal. “I would like to be an international consultant in bodies such as the Intergovernmental Panel on Climate Change (IPCC), and the United Nations Framework Convention on Climate Change (UNFCCC), as they play a key role in making decisions on climate change,” Lekhooa highlighted.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept